Response rates to curative-intent 2L treatment in MER and LEO cohorts
| 2L therapy . | MER (N = 949) . | LEO (N = 2755) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PPD (n = 40) . | EOT PR (n = 40) . | Early relapse (n = 52) . | Total (n = 132) . | P . | PPD (n = 145) . | EOT PR (n = 66) . | Early relapse (n = 97) . | Total (n = 308) . | P . | |
| n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | |||
| Curative intent | 35 (90.0) | 32 (86.5) | 38 (74.5) | 105 (82.8) | .174 | 102 (70.8) | 41 (63.1) | 49 (51.0) | 192 (63.0) | .040 |
| Non-curative intent | 4 (10.0) | 5 (13.5) | 13 (25.5) | 22 (17.2) | 42 (29.2) | 24 (36.9) | 47 (49.0) | 113 (37.0) | ||
| Missing/ n/a | 1 | 3 | 1 | 4 | 1 | 1 | 1 | 3 | ||
| 2L therapy . | MER (N = 949) . | LEO (N = 2755) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PPD (n = 40) . | EOT PR (n = 40) . | Early relapse (n = 52) . | Total (n = 132) . | P . | PPD (n = 145) . | EOT PR (n = 66) . | Early relapse (n = 97) . | Total (n = 308) . | P . | |
| n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | |||
| Curative intent | 35 (90.0) | 32 (86.5) | 38 (74.5) | 105 (82.8) | .174 | 102 (70.8) | 41 (63.1) | 49 (51.0) | 192 (63.0) | .040 |
| Non-curative intent | 4 (10.0) | 5 (13.5) | 13 (25.5) | 22 (17.2) | 42 (29.2) | 24 (36.9) | 47 (49.0) | 113 (37.0) | ||
| Missing/ n/a | 1 | 3 | 1 | 4 | 1 | 1 | 1 | 3 | ||
| Response rate to 2L therapya . | n (%) . | n (%) . | n (%) . | n (%) . | P . | n (%) . | n (%) . | n (%) . | n (%) . | P . |
|---|---|---|---|---|---|---|---|---|---|---|
| Curative intent | n = 35 | n = 32 | n = 38 | n = 105 | .002 | n = 102 | n = 41 | n = 49 | n = 192 | ≤.001 |
| CR | 3 (8.6) | 5 (16.6) | 16 (42.1) | 24 (23.5) | 23 (23.9) | 15 (38.5) | 31 (66.0) | 69 (37.9) | ||
| PR | 11 (31.4) | 15 (50.0) | 11 (28.9) | 37 (36.3) | 22 (22.9) | 14 (35.9) | 6 (12.7) | 42 (23.1) | ||
| SD | 1 (2.9) | 2 (6.7) | 3 (7.9) | 6 (5.9) | 6 (6.3) | 1 (2.6) | 2 (4.3) | 9 (4.9) | ||
| PD | 19 (57.1) | 8 (26.7) | 7 (18.9) | 34 (34.3) | 45 (46.9) | 9 (23.0) | 8 (17.0) | 62 (34.1) | ||
| Missing | 1 | 2 | 1 | 4 | 6 | 2 | 2 | 10 | ||
| Non-curative intent | n = 4 | n = 5 | n = 13 | n = 22 | .243 | n = 42 | n = 24 | n = 47 | n = 113 | .045 |
| CR | 0 (0) | 1 (50.0) | 1 (11.1) | 2 (14.3) | 3 (9.6) | 3 (25.0) | 13 (36.1) | 19 (21.6) | ||
| PR | 1 (33.3) | 0 | 4 (44.4) | 5 (35.7) | 5 (16.1) | 2 (16.7) | 11 (30.6) | 18 (20.5) | ||
| SD | 1 (33.3) | 1 (50) | 0 | 2 (14.3) | 3 (9.6) | 3 (25.0) | 2 (5.5) | 8 (9.1) | ||
| PD | 1 (33.3) | 0 | 4 (44.4) | 5 (35.7) | 20 (64.5) | 4 (33.3) | 10 (27.8) | 34 (38.6) | ||
| Not applicableb/ missing | 1 | 3 | 4 | 8 | 11 | 12 | 11 | 34 |
| Response rate to 2L therapya . | n (%) . | n (%) . | n (%) . | n (%) . | P . | n (%) . | n (%) . | n (%) . | n (%) . | P . |
|---|---|---|---|---|---|---|---|---|---|---|
| Curative intent | n = 35 | n = 32 | n = 38 | n = 105 | .002 | n = 102 | n = 41 | n = 49 | n = 192 | ≤.001 |
| CR | 3 (8.6) | 5 (16.6) | 16 (42.1) | 24 (23.5) | 23 (23.9) | 15 (38.5) | 31 (66.0) | 69 (37.9) | ||
| PR | 11 (31.4) | 15 (50.0) | 11 (28.9) | 37 (36.3) | 22 (22.9) | 14 (35.9) | 6 (12.7) | 42 (23.1) | ||
| SD | 1 (2.9) | 2 (6.7) | 3 (7.9) | 6 (5.9) | 6 (6.3) | 1 (2.6) | 2 (4.3) | 9 (4.9) | ||
| PD | 19 (57.1) | 8 (26.7) | 7 (18.9) | 34 (34.3) | 45 (46.9) | 9 (23.0) | 8 (17.0) | 62 (34.1) | ||
| Missing | 1 | 2 | 1 | 4 | 6 | 2 | 2 | 10 | ||
| Non-curative intent | n = 4 | n = 5 | n = 13 | n = 22 | .243 | n = 42 | n = 24 | n = 47 | n = 113 | .045 |
| CR | 0 (0) | 1 (50.0) | 1 (11.1) | 2 (14.3) | 3 (9.6) | 3 (25.0) | 13 (36.1) | 19 (21.6) | ||
| PR | 1 (33.3) | 0 | 4 (44.4) | 5 (35.7) | 5 (16.1) | 2 (16.7) | 11 (30.6) | 18 (20.5) | ||
| SD | 1 (33.3) | 1 (50) | 0 | 2 (14.3) | 3 (9.6) | 3 (25.0) | 2 (5.5) | 8 (9.1) | ||
| PD | 1 (33.3) | 0 | 4 (44.4) | 5 (35.7) | 20 (64.5) | 4 (33.3) | 10 (27.8) | 34 (38.6) | ||
| Not applicableb/ missing | 1 | 3 | 4 | 8 | 11 | 12 | 11 | 34 |